Literature DB >> 10716067

A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition.

X J Zhao1, T Ishizaki.   

Abstract

Our previous study showed that several drugs inhibited quinine 3-hydroxylation, a cytochrome P450 (CYP) 3A4-mediated reaction, in vitro. In this extended study, 13 drugs were selected and tested by human liver microsomes in order to further determine their respective inhibition constant (Ki) and type of inhibition. According to the apparent Ki values, the inhibitory rank order of these tested drugs was as follows: ketoconazole > doxycycline > omeprazole > tetracycline > troleandomycin (with pre-incubation) > primaquine > troleandomycin (without pre-incubation) > nifedipine > erythromycin > verapamil > oleandomycin > diltiazem > cimetidine > hydralazine. Among these drugs, doxycycline, tetracycline, ketoconazole, nifedipine and hydralazine were judged as mixed inhibitors; whereas, the remaining other drugs tested were judged as competitive inhibitors. When the plasma/serum concentrations possibly attained after their usual therapeutic doses were taken into account, tetracycline, doxycycline, omeprazole, ketoconazole, nifedipine, troleandomycin and erythromycin are likely to be inhibitors of quinine metabolism in patients when these drugs are co-administrated with quinine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10716067     DOI: 10.1007/BF03190031

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  34 in total

Review 1.  Drug treatment and prevention of malaria.

Authors:  N J White
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.

Authors:  X J Zhao; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

Review 3.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

4.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

Authors:  T Shimada; H Yamazaki; M Mimura; Y Inui; F P Guengerich
Journal:  J Pharmacol Exp Ther       Date:  1994-07       Impact factor: 4.030

Review 5.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

6.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.

Authors:  K Chiba; K Kobayashi; K Manabe; M Tani; T Kamataki; T Ishizaki
Journal:  J Pharmacol Exp Ther       Date:  1993-07       Impact factor: 4.030

7.  The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly.

Authors:  J R Dyer; T M Davis; C Giele; T Annus; P Garcia-Webb; J Robson
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

8.  Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs.

Authors:  K N Bangchang; J Karbwang; D J Back
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

9.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

Authors:  T Andersson; J O Miners; M E Veronese; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

10.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

View more
  2 in total

1.  Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.

Authors:  Mikiko Shimizu; Tsukasa Uno; Norio Yasui-Furukori; Kazunobu Sugawara; Tomonori Tateishi
Journal:  Eur J Clin Pharmacol       Date:  2006-06-17       Impact factor: 2.953

2.  Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria.

Authors:  Teerachat Sae-Heng; Rajith Kumar Reddy Rajoli; Marco Siccardi; Juntra Karbwang; Kesara Na-Bangchang
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.